<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Röllig, Christoph</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Sorafenib as Effective Treatment for Newly Diagnosed AML in Younger Patients</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">8-9</style></pages><abstract><style  face="normal" font="default" size="100%">Acute myeloid leukemia, a common form of leukemia with a high mortality rate, is difficult to treat. In the SORAML trial, sorafenib, a multikinase inhibitor, prolonged event-free and relapse-free survival compared with a placebo in younger patients with acute myeloid leukemia. However, this benefit was accompanied by a higher rate of infections and bleeding.</style></abstract><number><style face="normal" font="default" size="100%">55</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>